Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]
Awaiting development
Reference number: GID-TA11670
Expected publication date: TBC
Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-May 2027 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately mid-July 2027.